UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

Diabetes, obesity & metabolism, 2018-02, Vol.20 (S1), p.22-33

Aroda, Vanita R.

2018

Volltextzugriff (PDF)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2022-11, Vol.45 (11), p.2753-2786

2022

Volltextzugriff (PDF)

2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S19-S40

2023

Volltextzugriff (PDF)

The Joy of Clinical Trials

Academic medicine, 2022-11, Vol.97 (11), p.1672-1672

Aroda, Vanita R

2022

Volltextzugriff (PDF)

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S140-S157

2023

Volltextzugriff (PDF)

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

Diabetes care, 2022-04, Vol.45 (4), p.766-768

2022

Volltextzugriff (PDF)

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetologia, 2022-12, Vol.65 (12), p.1925-1966

2022

Volltextzugriff (PDF)

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

The lancet. Diabetes & endocrinology, 2018-04, Vol.6 (4), p.275-286

2018

Volltextzugriff (PDF)

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Diabetes care, 2019-09, Vol.42 (9), p.1724-1732

2019

Volltextzugriff (PDF)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The lancet. Diabetes & endocrinology, 2017-05, Vol.5 (5), p.355-366

2017

Volltextzugriff (PDF)

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Diabetes care, 2018-02, Vol.41 (2), p.258-266

2018

Volltextzugriff (PDF)

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Diabetes care, 2016-11, Vol.39 (11), p.1972-1980

2016

Volltextzugriff (PDF)

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S191-S202

2023

Volltextzugriff (PDF)

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

Diabetes care, 2019-12, Vol.42 (12), p.2262-2271

2019

Volltextzugriff (PDF)

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S128-S139

2023

Volltextzugriff (PDF)

Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study

The journal of clinical endocrinology and metabolism, 2016-04, Vol.101 (4), p.1754-1761

2016

Volltextzugriff (PDF)

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Clinical therapeutics, 2012-06, Vol.34 (6), p.1247-1258.e22

2012

Volltextzugriff (PDF)

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S49-s67.2

2023

Volltextzugriff (PDF)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Reviews in endocrine & metabolic disorders, 2022-10, Vol.23 (5), p.979-994

2022

Volltextzugriff (PDF)

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-08, Vol.402 (10403), p.705-719

2023

Volltextzugriff (PDF)

6. Glycemic Targets: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S97-S110

2023

Volltextzugriff (PDF)

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Diabetes, obesity & metabolism, 2019-10, Vol.21 (10), p.2203-2210

2019

Volltextzugriff (PDF)

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment

Diabetes, obesity & metabolism, 2022-12, Vol.24 (12), p.2297-2308

2022

Volltextzugriff (PDF)

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S158-S190

2023

Volltextzugriff (PDF)

7. Diabetes Technology: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S111-S127

2023

Volltextzugriff (PDF)

1 – 25 von 306

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(285)

Publikationsform

Artikel
(306)

Sprache

Englisch
(306)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(163)
Life Sciences & Biomedicine
(162)
Humans
(142)
Endocrinology & Metabolism
(125)
Diabetes
(117)
Diabetes Mellitus
(82)
Female
(65)
Male
(55)
Middle Aged
(51)
Diabetes Mellitus, Type 2 - Drug Therapy
(48)
Clinical Trials
(47)
Insulin
(47)
Type 2 Diabetes
(44)
Endocrinology
(43)
Adult
(42)
Aged
(38)
Standard Of Care
(38)
Antidiabetics
(37)
Reference Standards
(36)
Societies, Medical
(36)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023

The Joy of Clinical Trials

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023

Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

6. Glycemic Targets: Standards of Care in Diabetes-2023

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023

7. Diabetes Technology: Standards of Care in Diabetes-2023

Suchergebnisse filtern